Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN), with the primary endpoint met: a statistically significant and clinically meaningful reduction in proteinuria versus placebo at 37 weeks.
Study Milestone Snapshot
| Item | Detail |
|---|---|
| Company | Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) |
| Asset | Sefaxersen – investigational, licensed from Ionis for complement‑mediated diseases |
| Study | Phase III IMAgINATION, ongoing; prespecified interim analysis |
| Population | Adults with primary IgA nephropathy (IgAN) |
| Primary Endpoint | Proteinuria reduction vs. placebo at week 37, measured by 24‑hour urine protein‑to‑creatinine ratio (UPCR) – met, statistically significant and clinically meaningful |
| Safety | Consistent with previously reported data; no new safety signals |
| Next Milestone | Blinded continuation to assess change in kidney function (eGFR) at week 105 (two years) |
Drug Profile & Mechanism of Action
- Modality: Liver‑directed antisense oligonucleotide (ASO) – highly specific; the first mRNA‑targeted therapy for IgAN.
- Target: Factor B mRNA – sefaxersen inhibits hepatic production of complement factor B, a key amplifier of the alternative complement pathway implicated in IgAN pathogenesis.
- Origin: Licensed by Roche from Ionis Pharmaceuticals for the treatment of complement‑mediated diseases.
- Differentiation: By suppressing factor B synthesis upstream at the mRNA level, sefaxersen represents a mechanistically distinct approach versus endothelin/angiotensin pathway agents and other late‑stage complement modulators in IgAN.
Clinical Evidence – Phase III IMAgINATION Interim Analysis
| Endpoint | Result (Sefaxersen) | Comparator | Interpretation |
|---|---|---|---|
| 24‑h UPCR reduction at week 37 (primary) | Statistically significant & clinically meaningful improvement | Placebo | Primary endpoint met; magnitude not disclosed |
| Safety & tolerability | Consistent with previously reported data | – | No new safety signals identified |
| eGFR change at week 105 (ongoing) | Not yet read out | Placebo | Blinded continuation to confirm long‑term kidney function preservation |
The interim analysis of IMAgINATION demonstrated that adults with primary IgAN receiving sefaxersen achieved significantly greater proteinuria reduction than placebo at 37 weeks, as measured by 24‑hour UPCR. Proteinuria is a key indicator of kidney damage, and a reduction in UPCR is strongly associated with preservation of long‑term kidney function — the basis on which regulators have accepted proteinuria as a surrogate endpoint for accelerated approval pathways in IgAN. The study will continue in blinded fashion to evaluate the change in eGFR at week 105.
Market Impact & Outlook
- IgAN Landscape: IgA nephropathy is the most common primary glomerulonephritis worldwide, with a substantial fraction of patients progressing toward kidney failure; validated disease‑modifying options remain limited, making a first‑in‑class mRNA‑targeted mechanism a significant addition to the competitive field.
- Regulatory Pathway Potential: A statistically significant UPCR reduction at week 37 aligns with the surrogate endpoint framework used for recent accelerated approvals in IgAN, positioning sefaxersen for potential regulatory submissions ahead of the week‑105 eGFR readout — timing not disclosed.
- Complement Franchise Value: The win strengthens Roche’s complement‑mediated disease portfolio built around the Ionis license, complementing the company’s broader renal and immunology pipeline.
- Competitive Dynamics: Sefaxersen would compete with recently approved and late‑stage IgAN therapies spanning endothelin receptor antagonism, targeted‑release budesonide, and other complement inhibitors — with factor B suppression offering a differentiated upstream mechanism.
- Next Steps: Completion of the blinded two‑year eGFR assessment at week 105; full interim dataset, magnitude of UPCR reduction, and filing plans were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory submissions and approvals, kidney‑function outcomes, and commercial expectations for sefaxersen in IgA nephropathy. Actual results may differ materially due to risks including long‑term efficacy and safety findings, regulatory review outcomes, competitive dynamics, and market conditions.-Fineline Info & Tech
